Effect of Rosuvastatin on serum Vaspin, ROCK activity and FMD in patients with CHD and its clinical significance
LIU Kun
ZHAO Yun-feng
LI Gong-hao
Abstract：Objective To study the effect of Rosuvastatin on coronary heart disease (CHD) patients on serum vaspin (Vaspin), Rho kinase (ROCK) activity, brachial artery flow mediated dilation (FMD) effect. Methods From July 2015 to July 2016 in 120 patients with CHD in our hospital, a prospective randomized study method divided into Rosuvastatin group and Atorvastatin group with 60 cases in each group, two groups of patients were treated with the same basic treatment, comparing the two groups after 8 weeks of treatment, serum Vaspin, ROCK activity, FMD index. Results After treatment, Rosuvastatin group TG (1.20 ±0.35)mmol/L, TC (4.41 ± 0.85)mmol/L, LDL-C (1.56±0.45)mmol/L, HDL-C (1.29±0.22)mmol/L, Atorvastatin group TG (1.28±0.37) mmol/L, TC(4.60±0.76)mmol/L, LDL-C(1.71±0.48)mmol/L, HDL-C(1.22±0.27)mmol/L, comparison the dif-ference was not statistically significant(P>0.05). After treatment, the ROCK activity(40.8±6.3)% in Rosuvastatin group was lower than that in Atorvastatin group(45.2±7.0)%(P<0.05), the FMD(7.86±1.59)% and serum Vaspin (1.74±0.32)ng/ml in Rosuvastatin group were higher than that of Atorvastatin group FMD (6.82±1.63)%, serum Vaspin(1.48±0.39)ng/ml(P<0.05), the serum IL-6 of Rosuvastatin group(200.7±32.5)pg/ml, IL-10(20.9± 2.4)ng/ml, TNF-α(2.21±0.39) was lower than Atorvastatin group IL-6(228.1±34.0)pg/ml, IL-10(22.6±2.8)ng/ml, TNF-α(2.65±0.44)ng/ml(P<0.05). Conclusion Rosuvastatin can inhibit the activity of ROCK, increase the lev-el of FMD and Vaspin, and decrease the level of serum inflammatory factors in patients with CHD.
Keywords：Coronary heart diseaseSerine proteinase inhibitorRho kinaseDiastolic function
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 655-659 )